Sumoylation at the host-pathogen interface

Biomolecules

Volumn 2, Issue 2, 2012, Pages 203-227

  Wilson, Van G ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

Bacteria; Immunity; SIMs; SUMO; Virus

Indexed keywords

INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 7; PROTEIN P53; PROTEIN UBC9; RETINOIC ACID INDUCIBLE PROTEIN I; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; SUMO PROTEIN; TOLL LIKE RECEPTOR; TRIPARTITE MOTIF PROTEIN 5;

CHICK EMBRYO LETHAL ORPHAN VIRUS; ENZYMOLOGY; HERPES SIMPLEX VIRUS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOPRECIPITATION; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; NONHUMAN; PATHOGEN LOAD; REVIEW; SUMOYLATION; VARICELLA ZOSTER VIRUS; XANTHOMONAS CAMPESTRIS;

EID: 85016352154     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom2020203     Document Type: Review

References (145)

1. Yaniv, M. Small DNA tumour viruses and their contributions to our understanding of transcription control. Virology 2009, 384, 369-374.
2. Lazo, P.A.; Santos, C.R. Interference with p53 functions in human viral infections, a target for novel antiviral strategies? Rev. Med. Virol. 2011, 21, 285-300.
3. Felsani, A.; Mileo, A.M.; Paggi, M.G. Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene 2006, 25, 5277-5285.
4. Isaacson, M.K.; Ploegh, H.L. Ubiquitination, ubiquitin-like modifiers, and deubiquitination in viral infection. Cell Host Microbe 2009, 5, 559-570.
5. Ohsumi, Y. Molecular dissection of autophagy: Two ubiquitin-like systems. Nat. Rev. Mol. Cell Biol. 2001, 2, 211-216.
6. Kamitani, T.; Kito, K.; Nguyen, H.P.; Yeh, E.T. Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein. J. Biol. Chem. 1997, 272, 28557-28562.
7. Loeb, K.R.; Haas, A.L. The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J. Biol. Chem. 1992, 267, 7806-7813.
8. Boddy, M.N.; Howe, K.; Etkin, L.D.; Solomon, E.; Freemont, P.S. Pic 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene 1996, 13, 971-982.
9. Matunis, M.J.; Coutavas, E.; Blobel, G. A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J. Cell Biol. 1996, 135, 1457-1470.
10. Okura, T.; Gong, L.; Kamitani, T.; Wada, T.; Okura, I.; Wei, C.F.; Chang, H.M.; Yeh, E.T. Protection against Fas/Apo-1-and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J. Immunol. 1996, 157, 4277-4281.
11. Shen, Z.Y.; Pardingtonpurtymun, P.E.; Comeaux, J.C.; Moyzis, R.K.; Chen, D.J. Ubl1, a human ubiquitin-like protein associating with human Rad51/Rad52 proteins. Genomics 1996, 36, 271-279.
12. Boggio, R.; Chiocca, S. Viruses and sumoylation: Recent highlights. Curr. Opin. Micro. 2006, 9, 430-436.
13. Deyrieux, A.; Wilson, V.G. Viral Interplay with the Host Sumoylation System. In Sumo Regulation of Cellular Processes; Wilson, V.G., Ed.; Springer: Dordrecht, The Netherlands, 2009; pp. 315-329.
14. Bekes, M.; Drag, M. Trojan horse strategies used by pathogens to influence the small ubiquitin-like modifier (SUMO) system of host eukaryotic cells. J. Innate Immun. 2012, 4, 159-167
15. Melchior, F. SUMO-nonclassical ubiquitin. Ann. Rev. Cell Dev. Biol. 2000, 16, 591-626.
16. Muller, S.; Hoege, C.; Pyrowolakis, G.; Jentsch, S. SUMO, ubiquitin's mysterious cousin. Nat. Rev. Mol. Cell Biol. 2001, 2, 202-210.
17. Saitoh, H.; Pu, R.T.; Dasso, M. SUMO-1: Wrestling with a new ubiquitin-related modifier. Trends Biochem. Sci. 1997, 22, 374-376.
18. Lapenta, V.; Chiurazzi, P.; van der Spek, P.; Pizzuti, A.; Hanaoka, F.; Brahe, C. Smt3a, a human homologue of the s. Cerevisiae Smt3 gene, maps to chromosome 21qter and defines a novel gene family. Genomics 1997, 40, 362-366.
19. Bohren, K.M.; Nadkarni, V.; Song, J.H.; Gabbay, K.H.; Owerbach, D. A m55v polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type i diabetes mellitus. J. Biol. Chem. 2004, 279, 27233-27238.
20. Wang, C.Y.; She, J.X. SUMO4 and its role in type 1 diabetes pathogenesis. Diabetes-Metab. Res. Rev. 2008, 24, 93-102.
21. Desterro, J.M.; Thomson, J.; Hay, R.T. Ubc9 conjugates SUMO but not ubiquitin. FEBS Lett. 1997, 417, 297-300.
22. Saitoh, H.; Sparrow, D.B.; Shiomi, T.; Pu, R.T.; Nishimoto, T.; Mohun, T.J.; Dasso, M. Ubc9p and the conjugation of SUMO-1 to RanGAP1 and RanBP2. Curr. Biol. 1998, 8, 121-124.
23. Desterro, J.M.P.; Rodriguez, M.S.; Kemp, G.D.; Hay, R.T. Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. J. Biol. Chem. 1999, 274, 10618-10624.
24. Chakrabarti, S.R.; Sood, R.; Ganguly, S.; Bohlander, S.; Shen, Z.Y.; Nucifora, G. Modulation of Tel transcription activity by interaction with the ubiquitin-conjugating enzyme Ubc9. Proc. Natl. Acad. Sci. USA 1999, 96, 7467-7472.
25. Hateboer, G.; Hijmans, E.M.; Nooij, J.B.; Schlenker, S.; Jentsch, S.; Bernards, R. MUbc9, a novel adenovirus E1A-interacting protein that complements a yeast cell cycle defect. J. Biol. Chem. 1996, 271, 25906-25911.
26. Poukka, H.; Aarnisalo, P.; Karvonen, U.; Palvimo, J.J.; Janne, O.A. Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription. J. Biol. Chem. 1999, 274, 19441-19446.
27. Takahashi, Y.; Kahyo, T.; Toh-e, A.; Yasuda, H.; Kikuchi, Y. Yeast ull1/siz1 is a novel SUMO1/Smt3 ligase for septin components and functions as an adaptor between conjugating enzyme and substrates. J. Biol. Chem. 2001, 276, 48973-48977.
28. Takahashi, Y.; Toh-e, A.; Kikuchi, Y. A novel factor required for the SUMO1/Sm3 conjugation of yeast septins. Gene 2001, 275, 223-231.
29. Sachdev, S.; Bruhn, L.; Sieber, H.; Pichler, A.; Melchior, F.; Grosschedl, R. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses lef1 activity by sequestration into nuclear bodies. Genes Dev. 2001, 15, 3088-3103.
30. Pichler, A.; Gast, A.; Seeler, J.S.; Dejean, A.; Melchior, F. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 2002, 108, 109-120.
31. Kagey, M.H.; Melhuish, T.A.; Wotton, D. The polycomb protein Pc2 is a SUMO E3 ligase. Cell 2003, 113, 127-137.
32. Weger, S.; Hammer, E.; Heilbronn, R. Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo. FEBS Lett. 2005, 579, 5007-5012.
33. Chu, Y.; Yang, X. SUMO E3 ligase activity of TRIM proteins. Oncogene 2011, 30, 1108-1116.
34. Yeh, E.T.H. Sumoylation and de-sumoylation: Wrestling with life's processes. J. Biol. Chem. 2009, 284, 8223-8227.
35. Best, J.L.; Ganiatsas, S.; Agarwal, S.; Changou, A.; Salomoni, P.; Shirihai, O.; Meluh, P.B.; Pandolfi, P.P.; Zon, L.I. SUMO-1 protease-1 regulates gene transcription through PML. Mol. Cell 2002, 10, 843-855.
36. Gong, L.M.; Millas, S.; Maul, G.G.; Yeh, E.T.H. Differential regulation of sentrinized proteins by a novel sentrin-specific protease. J. Biol. Chem. 2000, 275, 3355-3359.
37. Nishida, T.; Kaneko, F.; Kitagawa, M.; Yasuda, H. Characterization of a novel mammalian SUMO-1/Smt3-specific isopeptidase, a homologue of rat Axam, which is an axin-binding protein promoting beta-catenin degradation. J. Biol. Chem. 2001, 276, 39060-39066.
38. Kadoya, T.; Yamamoto, H.; Suzuki, T.; Yukita, A.; Fukui, A.; Michiue, T.; Asahara, T.; Tanaka, K.; Asashima, M.; Kikuchi, A. Desumoylation activity of Axam, a novel axin-binding protein, is involved in downregulation of beta-catenin. Mol. Cell. Biol. 2002, 22, 3803-3819.
39. Kim, K.I.; Baek, S.H.; Jeon, Y.J.; Nishimori, S.; Suzuki, T.; Uchida, S.; Shimbara, N.; Saitoh, H.; Tanaka, K.; Chung, C.H. A new SUMO-1-specific protease, Susp1, that is highly expressed in reproductive organs. J. Biol. Chem. 2000, 275, 14102-14106.
40. Wilson, V.G. SUMO Regulation of Cellular Processes. Springer: Dordrecht, The Netherlands, 2009; p 339.
41. Rajan, S.; Plant, L.D.; Rabin, M.L.; Butler, M.H.; Goldstein, S.A.N. Sumoylation silences the plasma membrane leak k+ channel K2p1. Cell 2005, 121, 37-47.
42. Dai, X.Q.; Kolic, J.; Marchi, P.; Sipione, S.; MacDonald, P.E. Sumoylation regulates kv2.1 and modulates pancreatic beta-cell excitability. J. Cell. Sci. 2009, 122, 775-779.
43. Makhnevych, T.; Sydorskyy, Y.; Xin, X.; Srikumar, T.; Vizeacoumar, F.J.; Jeram, S.M.; Li, Z.; Bahr, S.; Andrews, B.J.; Boone, C.; et al. Global map of SUMO function revealed by protein-protein interaction and genetic networks. Mol. Cell 2009, 33, 124-135.
44. Agbor, T.A.; Taylor, C.T. SUMO, hypoxia and the regulation of metabolism. Biochem. Soc. Trans. 2008, 36, 445-448.
45. Wimmer, P.; Schreiner, S.; Dobner, T. Human pathogens and the host cell sumoylation system. J. Virol. 2012, 86, 642-654.
46. Thompson, M.R.; Kaminski, J.J.; Kurt-Jones, E.A.; Fitzgerald, K.A. Pattern recognition receptors and the innate immune response to viral infection. Viruses 2011, 3, 920-940.
47. Mi, Z.; Fu, J.; Xiong, Y.; Tang, H. Sumoylation of RIG-1 positively regulates the type I interferon signaling. Protein Cell 2010, 1, 275-283.
48. Fu, J.H.; Xiong, Y.B.; Xu, Y.L.; Cheng, G.H.; Tang, H. Mda5 is sumoylated by PIAS2 beta in the upregulation of type i interferon signaling. Mol. Immunol. 2011, 48, 415-422.
49. Kim, J.H.; Sung, K.S.; Jung, S.M.; Lee, Y.S.; Kwon, J.Y.; Choi, C.Y.; Park, S.H. Pellino-1, an adaptor protein of interleukin-1 receptor/toll-like receptor signaling, is sumoylated by Ubc9. Mol. Cells 2011, 31, 85-89.
50. Kubota, T.; Matsuoka, M.; Chang, T.H.; Tailor, P.; Sasaki, T.; Tashiro, M.; Kato, A.; Ozato, K. Virus infection triggers sumoylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression. J. Biol. Chem. 2008, 283, 25660-25670.
51. Ran, Y.; Liu, T.T.; Zhou, Q.; Li, S.; Mao, A.P.; Li, Y.; Liu, L.J.; Cheng, J.K.; Shu, H.B. SENP2 negatively regulates cellular antiviral response by desumoylating IRF3 and conditioning it for ubiquitination and degradation. J. Mol. Cell Biol. 2011, 3, 283-292.
52. Boo, K.H.; Yang, J.S. Intrinsic cellular defenses against virus infection by antiviral type I interferon. Yonsei Med. J. 2010, 51, 9-17.
53. Everett, R.D.; Chelbi-Alix, M.K. PML and PML nuclear bodies: Implications in antiviral defence. Biochimie 2007, 89, 819-830.
54. McNab, F.W.; Rajsbaum, R.; Stoye, J.P.; O'Garra, A. Tripartite-motif proteins and innate immune regulation. Curr. Opin. Immunol.2011, 23, 46-56.
55. Stremlau, M.; Owens, C.M.; Perron, M.J.; Kiessling, M.; Autissier, P.; Sodroski, J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in old world monkeys. Nature 2004, 427, 848-853.
56. Perron, M.J.; Stremlau, M.; Song, B.; Ulm, W.; Mulligan, R.C.; Sodroski, J. TRIM5alpha mediates the postentry block to n-tropic murine leukemia viruses in human cells. Proc. Natl. Acad. Sci. USA 2004, 101, 11827-11832.
57. Arriagada, G.; Muntean, L.N.; Goff, S.P. SUMO-interacting motifs of human TRIM5 alpha are important for antiviral activity. PLoS Pathog. 2011, 7, e1002019.
58. Geoffroy, M.C.; Chelbi-Alix, M.K. Role of promyelocytic leukemia protein in host antiviral defense. J. Interf. Cytokine Res. 2011, 31, 145-158.
59. Kyratsous, C.A.; Silverstein, S.J. Components of nuclear domain 10 bodies regulate varicella-zoster virus replication. J. Virol. 2009, 83, 4262-4274.
60. Djavani, M.; Rodas, J.; Lukashevich, I.S.; Horejsh, D.; Pandolfi, P.P.; Borden, K.L.B.; Salvato, M.S. Role of promyelocytic leukemia protein PML in the interferon sensitivity of lymphocytic choriomeningitis virus. J. Virol. 2001, 75, 6204-6208.
61. El Mchichi, B.; Regad, T.; Maroui, M.A.; Rodriguez, M.S.; Aminev, A.; Gerbaud, S.; Escriou, N.; Dianoux, L.; Chelbi-Alix, M.K. Sumoylation promotes PML degradation during encephalomyocarditis virus infection. J. Virol. 2010, 84, 11634-11645.
62. Blondel, D.; Regad, T.; Poisson, N.; Pavie, B.; Harper, F.; Pandolfi, P.P.; de The, H.; Chelbi-Alix, M.K. Rabies virus p and small p products interact directly with PML and reorganize PML nuclear bodies. Oncogene 2002, 21, 7957-7970.
63. Bonilla, W.V.; Pinschewer, D.D.; Klenerman, P.; Rousson, V.; Gaboli, M.; Pandolfi, P.P.; Zinkernagel, M.; Salvato, M.S.; Hengartner, H. Effects of promyelocytic leukemia protein on virus-host balance. J. Virol. 2002, 76, 3810-3818.
64. Tavalai, N.; Stamminger, T. Interplay between herpesvirus infection and host defense by PML nuclear bodies. Viruses 2009, 1, 1240-1264.
65. Cuchet-Lourenco, D.; Boutell, C.; Lukashchuk, V.; Grant, K.; Sykes, A.; Murray, J.; Orr, A.; Everett, R.D. SUMO pathway dependent recruitment of cellular repressors to herpes simplex virus type 1 genomes. PLoS Pathog. 2011, 7, e1002123.
66. Everett, R.D.; Parada, C.; Gripon, P.; Sirma, H.; Orr, A. Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100. J. Virol. 2008, 82, 2661-2672.
67. Boutell, C.; Cuchet-Lourenco, D.; Vanni, E.; Orr, A.; Glass, M.; McFarlane, S.; Everett, R.D. A viral ubiquitin ligase has substrate preferential SUMO targeted ubiquitin ligase activity that counteracts intrinsic antiviral defence. PLoS Pathog. 2011, 7, e1002245.
68. Kamitani, T.; Kito, K.; Nguyen, H.P.; Wada, H.; Fukuda-Kamitani, T.; Yeh, E.T. Identification of three major sentrinization sites in PML. J. Biol. Chem. 1998, 273, 26675-26682.
69. Wang, L.; Oliver, S.L.; Sommer, M.; Rajamani, J.; Reichelt, M.; Arvin, A.M. Disruption of PML nuclear bodies is mediated by ORF61 SUMO-interacting motifs and required for varicella-zoster virus pathogenesis in skin. PLoS Pathog. 2011, 7, e1002157.
70. Hotson, A.; Chosed, R.; Shu, H.J.; Orth, K.; Mudgett, M.B. Xanthomonas type III effector XopD targets SUMO-conjugated proteins in planta. Mol. Micro. 2003, 50, 377-389.
71. Roden, J.; Eardley, L.; Hotson, A.; Cao, Y.Y.; Mudgett, M.B. Characterization of the Xanthomonas Avrxv4 effector, a SUMO protease translocated into plant cells. Mol. Plant-Microbe Interact. 2004, 17, 633-643.
72. Kim, J.G.; Taylor, K.W.; Hotson, A.; Keegan, M.; Schmelz, E.A.; Mudgett, M.B. XopD SUMO protease affects host transcription, promotes pathogen growth, and delays symptom development in Xanthomonas-infected tomato leaves. Plant Cell 2008, 20, 1915-1929.
73. Chang, P.C.; Izumiya, Y.; Wu, C.Y.; Fitzgerald, L.D.; Campbell, M.; Ellison, T.J.; Lam, K.S.; Luciw, P.A.; Kung, H.J. Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a SUMO E3 ligase that is SIM-dependent and SUMO-2/3-specific. J. Biol. Chem. 2010, 285, 5266-5273.
74. Pennella, M.A.; Liu, Y.; Woo, J.L.; Kim, C.A.; Berk, A.J. Adenovirus E1B 55-kilodalton protein is a p53-SUMO1 E3 ligase that represses p53 and stimulates its nuclear export through interactions with promyelocytic leukemia nuclear bodies. J. Virol. 2010, 84, 12210-12225.
75. Muller, S.; Dobner, T. The adenovirus E1B-55k oncoprotein induces SUMO modification of p53. Cell Cycle 2008, 7, 754-758.
76. Izumiya, Y.; Ellison, T.J.; Yeh, E.T.H.; Jung, J.U.; Luciw, P.A.; Kung, H.J. Kaposi's sarcoma-associated herpesvirus K-bZIP represses gene transcription via SUMO modification. J. Virol. 2005, 79, 9912-9925.
77. Izumiya, Y.; Izumiya, C.; Van Geelen, A.; Wang, D.H.; Lam, K.S.; Luciw, P.A.; Kung, H.J. Kaposi's sarcoma-associated herpesvirus-encoded protein kinase and its interaction with K-bZIP. J. Virol. 2007, 81, 1072-1082.
78. Perry, J.J.P.; Tainer, J.A.; Boddy, M.N. A SIM-ultaneous role for SUMO and ubiquitin. Trends Biochem. Sci. 2008, 33, 201-208.
79. Viswanathan, K.; Fruh, K.; DeFilippis, V. Viral hijacking of the host ubiquitin system to evade interferon responses. Curr. Opin. Microbiol. 2010, 13, 517-523.
80. Boggio, R.; Colombo, R.; Hay, R.T.; Draetta, G.F.; Chiocca, S. A mechanism for inhibiting the SUMO pathway. Mol. Cell 2004, 16, 549-561.
81. Glotzer, J.B.; Saltik, M.; Chiocca, S.; Michou, A.I.; Moseley, P.; Cotten, M. Activation of heatshock response by an adenovirus is essential for virus replication. Nature 2000, 407, 207-211.
82. Colombo, R.; Boggio, R.; Seiser, C.; Draetta, G.F.; Chiocca, S. The adenovirus protein GAM1 interferes with sumoylation of histone deacetylase 1. EMBO Rep. 2002, 3, 1062-1068.
83. Boggio, R.; Passafaro, A.; Chiocca, S. Targeting SUMO E1 to ubiquitin ligases-a viral strategy to counteract sumoylation. J. Biol. Chem. 2007, 282, 15376-15382.
84. Garcia-Dominguez, M.; Reyes, J.C. SUMO association with repressor complexes, emerging routes for transcriptional control. Biochim. Biophys. Acta-Gene Reg. Mech. 2009, 1789, 451-459.
85. Boggio, R.; Chiocca, S. GAM1 and the SUMO pathway. Cell Cycle 2005, 4, 533-535.
86. Bischof, O.; Schwamborn, K.; Martin, N.; Werner, A.; Sustmann, C.; Grosschedl, R.; Dejean, A. The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol. Cell 2006, 22, 783-794.
87. Chang, T.H.; Kubota, T.; Matsuoka, M.; Jones, S.; Bradfute, S.B.; Bray, M.; Ozato, K. Ebola zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog. 2009, 5, e1000493.
88. Ribet, D.; Hamon, M.; Gouin, E.; Nahori, M.A.; Impens, F.; Neyret-Kahn, H.; Gevaert, K.; Vandekerckhove, J.; Dejean, A.; Cossart, P. Listeria monocytogenes impairs sumoylation for efficient infection. Nature 2010, 464, 1192-1195.
89. Heaton, P.R.; Deyrieux, A.F.; Bian, X.L.; Wilson, V.G. HPV E6 proteins target Ubc9, the SUMO conjugating enzyme. Virus Res. 2011, 158, 199-208.
90. Howie, H.L.; Katzenellenbogen, R.A.; Galloway, D.A. Papillomavirus E6 proteins. Virology 2009, 384, 324-334.
91. Marusic, M.B.; Mencin, N.; Licen, M.; Banks, L.; Grm, H.S.T. Modification of human papillomavirus minor capsid protein L2 by sumoylation. J. Virol. 2010, 84, 11585-11589.
92. Bentz, G.L.; Whitehurst, C.B.; Pagano, J.S. Epstein-barr virus latent membrane protein 1 (LMP1) c-terminal-activating region 3 contributes to LMP1-mediated cellular migration via its interaction with Ubc9. J. Virol. 2011, 85, 10144-10153.
93. Pal, S.; Santos, A.; Rosas, J.M.; Ortiz-Guzman, J.; Rosas-Acosta, G. Influenza A virus interacts extensively with the cellular sumoylation system during infection. Virus Res. 2011, 158, 12-27.
94. Yousef, A.F.; Fonseca, G.J.; Pelka, P.; Ablack, J.N.G.; Walsh, C.; Dick, F.A.; Bazett-Jones, D.P.; Shaw, G.S.; Mymryk, J.S. Identification of a molecular recognition feature in the E1A oncoprotein that binds the SUMO conjugase Ubc9 and likely interferes with polysumoylation. Oncogene 2010, 29, 4693-4704.
95. Knipscheer, P.; Flotho, A.; Klug, H.; Olsen, J.V.; van Dijk, W.J.; Fish, A.; Johnson, E.S.; Mann, M.; Sixma, T.K.; Pichler, A. Ubc9 sumoylation regulates SUMO target discrimination. Mol. Cell 2008, 31, 371-382.
96. Gomes, R.; Guerra-Sa, R.; Arruda, E. Coxsackievirus L35 induced apoptosis of HeLa cells: Effects on p53 and SUMO. Virology 2010, 396, 256-263.
97. Ledl, A.; Schmidt, D.; Muller, S. Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor. Oncogene 2005, 24, 3810-3818.
98. Macaluso, M.; Montanari, M.; Giordano, A. Rb family proteins as modulators of gene expression and new aspects regarding the interaction with chromatin remodeling enzymes. Oncogene 2006, 25, 5263-5267.
99. Chang, P.C.; Fitzgerald, L.D.; Van Geelen, A.; Izumiya, Y.; Ellison, T.J.; Wang, D.H.; Ann, D.K.; Luciw, P.A.; Kung, H.J. Kruppel-associated box domain-associated protein-1 as a latency regulator for Kaposi's sarcoma-associated herpesvirus and its modulation by the viral protein kinase. Cancer Res 2009, 69, 5681-5689.
100. Schultz, D.C.; Ayyanathan, K.; Negorev, D.; Maul, G.G.; Rauscher, F.J., 3rd. Setdb1: A novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to Hp1-mediated silencing of euchromatic genes by Krab zinc-finger proteins. Genes Dev. 2002, 16, 919-932.
101. Ivanov, A.V.; Peng, H.; Yurchenko, V.; Yap, K.L.; Negorev, D.G.; Schultz, D.C.; Psulkowski, E.; Fredericks, W.J.; White, D.E.; Maul, G.G.; et al. Phd domain-mediated E3 ligase activity directs intramolecular sumoylation of an adjacent bromodomain required for gene silencing. Mol. Cell 2007, 28, 823-837.
102. Li, X.; Lee, Y.K.; Jeng, J.C.; Yen, Y.; Schultz, D.C.; Shih, H.M.; Ann, D.K. Role for KAP1 serine 824 phosphorylation and sumoylation/desumoylation switch in regulating KAP1-mediated transcriptional repression. J. Biol. Chem. 2007, 282, 36177-36189.
103. Maul, G.G.; Negorev, D.; Bell, P.; Ishov, A.M. Properties and assembly mechanisms of ND10, PML bodies, or PODs [review]. J. Struct. Biol. 2000, 129, 278-287.
104. Ishov, A.M.; Sotnikov, A.G.; Negorev, D.; Vladimirova, O.V.; Neff, N.; Kamitani, T.; Yeh, E.T.H.; Strauss, J.F.; Maul, G.G. PML is critical for ND10 formation and recruits the PML-interacting protein Daxx to this nuclear structure when modified by SUMO-1. J. Cell. Biol. 1999, 147, 221-233.
105. Adamson, A.L.; Kenney, S. Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J. Virol. 2001, 75, 2388-2399.
106. Marcos-Villar, L.; Campagna, M.; Lopitz-Otsoa, F.; Gallego, P.; Gonzalez-Santamaria, J.; Gonzalez, D.; Rodriguez, M.S.; Rivas, C. Covalent modification by SUMO is required for efficient disruption of PML oncogenic domains by Kaposi's sarcoma-associated herpesvirus latent protein LANA2. J. Gen. Virol. 2011, 92, 188-194.
107. Ahn, J.H.; Hayward, G.S. The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells. J. Virol. 1997, 71, 4599-4613.
108. Muller, S.; Dejean, A. Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J. Virol. 1999, 73, 5137-5143.
109. Hagemeier, S.R.; Dickerson, S.J.; Meng, Q.; Yu, X.M.; Mertz, J.E.; Kenney, S.C. Sumoylation of the Epstein-Barr virus BZLF1 protein inhibits its transcriptional activity and is regulated by the virus-encoded protein kinase. J. Virol. 2010, 84, 4383-4394.
110. Marcos-Villar, L.; Lopitz-Otsoa, F.; Gallego, P.; Munoz-Fontela, C.; Gonzalez-Santamaria, J.; Campagna, M.; Shou-Jiang, G.; Rodriguez, M.S.; Rivas, C. Kaposi's sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene. J. Virol. 2009, 83, 8849-8858.
111. Lallemand-Breitenbach, V.; Jeanne, M.; Benhenda, S.; Nasr, R.; Lei, M.; Peres, L.; Zhou, J.; Zhu, J.; Raught, B.; de The, H. Arsenic degrades PML or PML-RAR alpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol. 2008, 10, 547-555.
112. Xu, Y.X.; Ahn, J.H.; Cheng, M.F.; Ap Rhys, C.M.; Chiou, C.J.; Zong, J.H.; Matunis, M.J.; Hayward, G.S. Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression. J. Virol. 2001, 75, 10683-10695.
113. Boutell, C.; Orr, A.; Everett, R.D. PML residue lysine 160 is required for the degradation of PML induced by herpes simplex virus type 1 regulatory protein ICP0. J. Virol. 2003, 77, 8686-8694.
114. Lee, H.R.; Kim, D.J.; Lee, J.M.; Choi, C.Y.; Ahn, B.Y.; Hayward, G.S.; Ahn, J.H. Ability of the human cytomegalovirus IE1 protein to modulate sumoylation of PML correlates with its functional activities in transcriptional regulation and infectivity in cultured fibroblast cells. J. Virol. 2004, 78, 6527-6542.
115. Kang, H.; Kim, E.T.; Lee, H.R.; Park, J.J.; Go, Y.Y.; Choi, C.Y.; Ahn, J.H. Inhibition of SUMO-independent PML oligomerization by the human cytomegalovirus IE1 protein. J. Gen. Virol. 2006, 87, 2181-2190.
116. Hofmann, H.; Floss, S.; Stamminger, T. Covalent modification of the transactivator protein IE2-p86 of human cytomegalovirus by conjugation to the ubiquitin-homologous proteins SUMO-1 and HSMT3b. J. Virol. 2000, 74, 2510-2524.
117. Ahn, J.-H.; Xu, Y.; Jang, W.-J.; Matunis, M.J.; Hayward, G.S. Evaluation of interactions of human cytomegalovirus immediate-early IE2 regulatory protein with small ubiquitin-like modifiers and their conjugation enzyme Ubc9. J. Virol. 2001, 75, 3859-3872.
118. Lee, J.M.; Kang, H.J.; Lee, H.R.; Choi, C.Y.; Jang, W.J.; Ahn, J.H. PIAS1 enhances SUMO-1 modification and the transactivation activity of the major immediate-early IE2 protein of human cytomegalovirus. FEBS Lett. 2003, 555, 322-328.
119. Kim, E.T.; Kim, Y.E.; Huh, Y.H.; Ahn, J.H. Role of noncovalent SUMO binding by the human cytomegalovirus IE2 transactivator in lytic growth. J. Virol. 2010, 84, 8111-8123.
120. Berndt, A.; Hofmann-Winkler, H.; Tavalai, N.; Hahn, G.; Stamminger, T. Importance of covalent and noncovalent SUMO interactions with the major human cytomegalovirus transactivator IE2p86 for viral infection. J. Virol. 2009, 83, 12881-12894.
121. Sourvinos, G.; Tavalai, N.; Berndt, A.; Spandidos, D.A.; Stamminger, T. Recruitment of human cytomegalovirus immediate-early 2 protein onto parental viral genomes in association with ND10 in live-infected cells. J. Virol. 2007, 81, 10123-10136.
122. Sternsdorf, T.; Jensen, K.; Will, H. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J. Cell Biol. 1997, 139, 1621-1634.
123. Jang, M.S.; Ryu, S.W.; Kim, E. Modification of Daxx by small ubiquitin-related modifier-1. Biochem. Biophys. Res. Commun. 2002, 295, 495-500.
124. Parkinson, J.; Everett, R.D. Alphaherpesvirus proteins related to herpes simplex virus type 1 ICP0 affect cellular structures and proteins. J. Virol. 2000, 74, 10006-10017.
125. Hwang, J.; Kalejta, R.F. Human cytomegalovirus protein pp71 induces Daxx sumoylation. J. Virol. 2009, 83, 6591-6598.
126. Zamborlini, A.; Coiffic, A.; Beauclair, G.; Delelis, O.; Paris, J.; Koh, Y.; Magne, F.; Giron, M.L.; Tobaly-Tapiero, J.; Deprez, E.; et al. Impairment of human immunodeficiency virus type-1 integrase sumoylation correlates with an early replication defect. J. Biol. Chem. 2011, 286, 21013-21022.
127. Endter, C.; Kzhyshkowska, J.; Stauber, R.; Dobner, T. SUMO-1 modification required for transformation by adenovirus type 5 early region 1B 55-kDa oncoprotein. Proc. Natl. Acad. Sci. USA 2001, 98, 11312-11317.
128. Weger, S.; Hammer, E.; Heilbronn, R. SUMO-1 modification regulates the protein stability of the large regulatory protein rep78 of adeno associated virus type 2 (AAV-2). Virology 2004, 330, 284-294.
129. Lamsoul, I.; Lodewick, J.; Lebrun, S.; Brasseur, R.; Burny, A.; Gaynor, R.B.; Bex, F. Exclusive ubiquitination and sumoylation on overlapping lysine residues mediate NF-kappa B activation by the human T-cell leukemia virus Tax oncoprotein. Mol. Cell. Biol. 2005, 25, 10391-10406.
130. Yueh, A.; Leung, J.; Bhattacharyya, S.; Perrone, L.A.; Pu, S.Y.; Goff, S.P. Interaction of moloney murine leukemia virus capsid with Ubc9 and PIASy mediates SUMO-1 addition required early in infection. J. Virol. 2006, 80, 342-352.
131. Gonzalez-Santamaria, J.; Campagna, M.; Garcia, M.A.; Marcos-Villar, L.; Gonzalez, D.; Gallego, P.; Lopitz-Otsoa, F.; Guerra, S.; Rodriguez, M.S.; Esteban, M.; et al. Regulation of vaccinia virus E3 protein by small ubiquitin-like modifier proteins. J. Virol. 2011, 85, 12890-12900.
132. Chang, L.K.; Lee, Y.H.; Cheng, T.S.; Hong, Y.R.; Lu, P.J.; Wang, J.J.; Wang, W.H.; Kuo, C.W.; Li, S.S.L.; Liu, S.T. Post-translational modification of Rta of Epstein-Barr virus by SUMO-1. J. Biol. Chem. 2004, 279, 38803-38812.
133. Rosendorff, A.; Illanes, D.; David, G.; Lin, J.; Kieff, E.; Johannsen, E. EBNA3c coactivation with EBNA2 requires a SUMO homology domain. J. Virol. 2004, 78, 367-377.
134. Tseng, C.H.; Cheng, T.S.; Shu, C.Y.; Jeng, K.S.; Lai, M.M.C. Modification of small hepatitis delta virus antigen by SUMO protein. J. Virol. 2010, 84, 918-927.
135. Rangasamy, D.; Wilson, V.G. Bovine papillomavirus E1 protein is sumoylated by the host cell Ubc9 protein. J. Biol. Chem. 2000, 275, 30487-30495.
136. Gravel, A.; Gosselin, J.; Flamand, L. Human herpesvirus 6 immediate-early 1 protein is a sumoylated nuclear phosphoprotein colocalizing with promyelocytic leukemia protein-associated nuclear bodies. J. Biol. Chem. 2002, 277, 19679-19687.
137. Stanton, R.; Fox, J.D.; Caswell, R.; Sherratt, E.; Wilkinson, G.W.G. Analysis of the human herpesvirus-6 immediate-early 1 protein. J. Gen. Virol. 2002, 83, 2811-2820.
138. Wu, Y.C.; Roark, A.A.; Bian, X.L.; Wilson, V.G. Modification of papillomavirus E2 proteins by the small ubiquitin-like modifier family members (SUMOs). Virology 2008, 378, 329-338.
139. Li, F.Q.S.; Xiao, H.; Tam, J.P.; Liu, D.X. Sumoylation of the nucleocapsid protein of severe acute respiratory syndrome coronavirus. FEBS Lett. 2005, 579, 2387-2396.
140. Gurer, C.; Berthoux, L.; Luban, J. Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1. J. Virol. 2005, 79, 910-917.
141. Sun, D.Y.; Xu, P.; He, B. Sumoylation of the P protein at K254 plays an important role in growth of parainfluenza virus 5. J. Virol. 2011, 85, 10261-10268.
142. Chen, S.C.; Chang, L.Y.; Wang, Y.W.; Chen, Y.C.; Weng, K.F.; Shih, S.R.; Shih, H.M. Sumoylation-promoted enterovirus 71 3C degradation correlates with a reduction in viral replication and cell apoptosis. J. Biol. Chem. 2011, 286, 31373-31384.
143. Palacios, S.; Perez, L.H.; Welsch, S.; Schleich, S.; Chmielarska, K.; Melchior, F.; Locker, J.K. Quantitative SUMO-1 modification of a vaccinia virus protein is required for its specific localization and prevents its self-association. Mol. Biol. Cell 2005, 16, 2822-2835.
144. Stallings, C.L.; Silverstein, S.J. Posttranslational modification and cell type-specific degradation of varicella-zoster virus ORF29p. J. Virol. 2006, 80, 10836-10846.
145. Pal, S.; Rosas, J.M.; Rosas-Acosta, G. Identification of the non-structural influenza A viral protein NS1a as a bona fide target of the small ubiquitin-like modifier by the use of dicistronic expression constructs. J. Virol. Meth. 2010, 163, 498-504.